Why do you keep asserting Anavex doesn't have a biomarker equivalent to what Eisai/Biogen have presented? The 2b/3 trial will be reporting on amyloid levels, per its design, and the company has reason to believe blarcamesine will act to prevent amyloid formation. As stupid as it sounds, Anavex might qualify for accelerated approval based on this possibility alone.
I hate that this post is probably dead on. So we have another 18 months to wait. It never ends. Why would he use the term "aggressive" when his approach is years out?
News 
Market Data 
Discover 
AI
